227 related articles for article (PubMed ID: 28526812)
1. Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis.
Dengler M; Staufer K; Huber H; Stauber R; Bantel H; Weiss KH; Starlinger P; Pock H; Klöters-Plachky P; Gotthardt DN; Rauch P; Lackner C; Stift J; Brostjan C; Gruenberger T; Kumada T; Toyoda H; Tada T; Weiss TS; Trauner M; Mikulits W
Oncotarget; 2017 Jul; 8(28):46234-46248. PubMed ID: 28526812
[TBL] [Abstract][Full Text] [Related]
2. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma.
Reichl P; Fang M; Starlinger P; Staufer K; Nenutil R; Muller P; Greplova K; Valik D; Dooley S; Brostjan C; Gruenberger T; Shen J; Man K; Trauner M; Yu J; Gao CF; Mikulits W
Int J Cancer; 2015 Jul; 137(2):385-394. PubMed ID: 25529751
[TBL] [Abstract][Full Text] [Related]
3. Soluble Axl Is a Novel Diagnostic Biomarker of Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection.
Song X; Wu A; Ding Z; Liang S; Zhang C
Cancer Res Treat; 2020 Jul; 52(3):789-797. PubMed ID: 32138467
[TBL] [Abstract][Full Text] [Related]
4. The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis.
Staufer K; Dengler M; Huber H; Marculescu R; Stauber R; Lackner C; Dienes HP; Kivaranovic D; Schachner C; Zeitlinger M; Wulkersdorfer B; Rauch P; Prager G; Trauner M; Mikulits W
Cell Death Dis; 2017 Oct; 8(10):e3135. PubMed ID: 29072690
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of Axl Receptor Shedding in Hepatocellular Carcinoma and Its Implication for Theranostics.
Holstein E; Binder M; Mikulits W
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30567378
[TBL] [Abstract][Full Text] [Related]
6. Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.
Motawi TK; Shaker OG; El-Maraghy SA; Senousy MA
PLoS One; 2015; 10(9):e0137706. PubMed ID: 26352740
[TBL] [Abstract][Full Text] [Related]
7. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
8. Development and potential application of a simultaneous multiplex assay of Golgi protein 73 and alpha-fetoprotein for hepatocellular carcinoma diagnosis.
Xiao J; Long F; Peng T; Hu LB; Cai H; Chen R; Chen WL
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3302-3310. PubMed ID: 31081083
[TBL] [Abstract][Full Text] [Related]
9. Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection.
Deng H; Fan X; Wang X; Zeng L; Zhang K; Zhang X; Li N; Han Q; Lv Y; Liu Z
Sci Rep; 2020 Nov; 10(1):20276. PubMed ID: 33219288
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of miR-331-3p and miR-23b-3p as serum biomarkers for hepatitis c virus-related hepatocellular carcinoma at early stage.
Sun Q; Li J; Jin B; Wang T; Gu J
Clin Res Hepatol Gastroenterol; 2020 Feb; 44(1):21-28. PubMed ID: 31053500
[TBL] [Abstract][Full Text] [Related]
11. Soluble AXL as a marker of disease progression and survival in melanoma.
Flem-Karlsen K; Nyakas M; Farstad IN; McFadden E; Wernhoff P; Jacobsen KD; Flørenes VA; Mælandsmo GM
PLoS One; 2020; 15(1):e0227187. PubMed ID: 31917795
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.
Liu D; Luo Y; Chen L; Chen L; Zuo D; Li Y; Zhang X; Wu J; Xi Q; Li G; Qi L; Yue X; Zhang X; Sun Z; Zhang N; Song T; Lu W; Guo H
Cancer Biol Med; 2021 Feb; 18(1):256-270. PubMed ID: 33628599
[TBL] [Abstract][Full Text] [Related]
13. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Efficacy and Possible Underlying Mechanisms of Noninvasive Clinical Markers in Hepatocellular Carcinoma.
Fu CX; Li J; Chen ZD; Cao YP; Zhang HL; Sui HT; Shan BC; Xu L; Zhou Y; Zhou M; Yang EY; Piao HX
J Clin Transl Hepatol; 2023 Aug; 11(4):889-898. PubMed ID: 37408805
[TBL] [Abstract][Full Text] [Related]
15. Accurate Determination of Soluble Axl by Enzyme-Linked Immunosorbent Assay.
Dengler M; Huber H; Müller CJ; Zellmer A; Rauch P; Mikulits W
Assay Drug Dev Technol; 2016 Nov; 14(9):543-550. PubMed ID: 27805424
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of alpha fetoprotein and HCCR-1, alone or in combination, in patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma.
Jirun P; Zhang G; Kim HK; Ha SA; Zhongtian J; Shishi Q; Zhuqingqing C; Lei G; Yoo J; Kim S; Park YG; Wang J; Yang Y; Xu Z; Huang Z; Lee YK; Song EY; Kim JW
Dis Markers; 2011; 30(6):307-15. PubMed ID: 21725159
[TBL] [Abstract][Full Text] [Related]
17. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.
Shen Q; Fan J; Yang XR; Tan Y; Zhao W; Xu Y; Wang N; Niu Y; Wu Z; Zhou J; Qiu SJ; Shi YH; Yu B; Tang N; Chu W; Wang M; Wu J; Zhang Z; Yang S; Gu J; Wang H; Qin W
Lancet Oncol; 2012 Aug; 13(8):817-26. PubMed ID: 22738799
[TBL] [Abstract][Full Text] [Related]
18. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.
Colli A; Nadarevic T; Miletic D; Giljaca V; Fraquelli M; Štimac D; Casazza G
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013346. PubMed ID: 33855699
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of Growth Arrest-Specific 6 protein and soluble AXL in patients with ST-segment elevation myocardial infarction.
Caldentey G; García De Frutos P; Cristóbal H; Garabito M; Berruezo A; Bosch X; San Antonio R; Flores-Umanzor E; Perea RJ; De Caralt TM; Rodríguez J; Ortiz-Pérez JT
Eur Heart J Acute Cardiovasc Care; 2019 Dec; 8(8):708-716. PubMed ID: 29119801
[TBL] [Abstract][Full Text] [Related]
20. Soluble AXL: a possible circulating biomarker for neurofibromatosis type 1 related tumor burden.
Johansson G; Peng PC; Huang PY; Chien HF; Hua KT; Kuo ML; Chen CT; Lee MJ
PLoS One; 2014; 9(12):e115916. PubMed ID: 25551830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
